News & Updates
On April 21st, we hosted our virtual networking meeting focused on the critical benefits of engaging a Statistician early in your clinical development program. Heather and Christopher along with their guest John Amrhein of McDougall Scientific facilitated a wonderful presentation and discussion around the many different and crucial benefits of engaging a Statistician early to…
Read More
Excerpt from the Article: MRI has grown in popularity as a tool to image the brain for various diseases or damage, leading to a heavy volume of scans for radiologists to interpret. Using an artificial intelligence (AI)-based system could help automate those interpretations to quickly identify the patients who need the most emergent care. “MRI…
Read More
Excerpt from the Press Release: PHILADELPHIA, April 15, 2021 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting…
Read More
Excerpt from the Press Release: BOSTON, April 15, 2021 /PRNewswire/ — NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for…
Read More
Excerpt from the Press Release: WARRINGTON, Pa., April 19, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO)…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and…
Read More
Excerpt from the Press Release: FRAMINGHAM, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and…
Read More
Excerpt from the Article: Leftover drops in vials of Moderna’s COVID-19 vaccine allowed a group of researchers from Stanford University to determine the sequence of the mRNA for SARS-CoV-2’s spike protein that is used in the immunization, Motherboard reported March 29. The sequence has been posted on the open-access website GitHub. “Sharing of sequence information…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine. “We are pleased that this new…
Read More
Excerpt from the Press Release: INDIANAPOLIS, April 8, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?